

RETRACTION

DOI: 10.3892/or.2023.8505

Isoquercitrin inhibits the progression of pancreatic cancer *in vivo* and *in vitro* by regulating opioid receptors and the mitogen-activated protein kinase signalling pathway

QUAN CHEN, PING LI, YONG XU, YANG LI and BO TANG

Oncol Rep 33: 840-848, 2015; DOI: 10.3892/or.2014.3626

Subsequent to the publication of the above article, a concerned reader drew to our attention that the flow cytometric plots shown in Fig. 2 had previously appeared in another article published in the journal *Oncology Reports* [Huang G, Tang B, Tang K, Dong X, Deng J, Liao L, Liao Z, Yang H and He S: Isoquercitrin inhibits the progression of liver cancer *in vivo* and *in vitro* via the MAPK signalling pathway. *Oncol Rep* 31: 2377-2384, 2014], suggesting that data purportedly showing results obtained under different experimental conditions had been derived from the same original source.

Given the errors that were identified in the compilation of Fig. 2 in this article, and the fact that all the data in this figure had been re-used from a previously published source, the Editor of *Oncology Reports* has decided that this article should be retracted from the publication owing to a lack of overall confidence in the presented data. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a satisfactory reply. The Editor apologizes to the readership for any inconvenience that might result from the retraction of this article.



This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.